RxDoctor Payments Data

Pratibha Anne, MD

Family Medicine · Shreveport, LANPI 1821228909

Payments from drug & device makers

$3,207in general payments, 2019–2025

Across 172 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$679
  • Boehringer Ingelheim$337
  • Novo Nordisk$314
  • GSK$297
  • Lilly USA, LLC$258
  • Jazz Pharmaceuticals Inc.$195
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,207100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,207 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$26,192
Medicare patients
108
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol26$28,195
JardianceEmpagliflozin22$19,749
OzempicSemaglutide18$16,932
MounjaroTirzepatide16$16,608
Rosuvastatin Calcium98$890
Gabapentin68$689
Naproxen14$621
SynthroidLevothyroxine Sodium12$574
Bumetanide14$565
Amlodipine Besylate115$494
Allopurinol48$447
Pravastatin Sodium21$395
Potassium Chloride34$354
Pantoprazole Sodium44$316
Metoprolol Succinate24$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$679$28,19526 claims
Boehringer IngelheimJardiance$337$19,74922 claims
Novo NordiskOzempic$314$16,93218 claims
Lilly USA, LLCMounjaro$258$16,60816 claims
AbbVieSynthroid$56$57412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →